IL6 and neoplasm: Current smokers, with disease stage IV, high baseline IL-6 (14.9 pg/mL, i.e., 95th percentile), and high tumor load (baseline TS: 17.8 cm, i.e., 95th percentile) would have a 68.3-fold higher Kin and consequently a less favorable higher inflammatory level compared to non-smokers with less aggressive disease stage (stage IIIB), lower baseline IL-6 (0.438 pg/mL, i.e., 5th percentile), and lower tumor load (baseline TS: 2.20 cm, i.e., 5th percentile).